Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2021-05-30 Regulatory Filings
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Chairman's letter to shareholders 1 page 108.7KB
Regulatory Filings Classification · 90% confidence The document is a letter from the Chairman to shareholders providing an update on the company's commercialisation strategy, clinical validation, pilot agreements, and outlook. It discusses business progress and future plans but does not contain financial statements, detailed financial analysis, or regulatory disclosures. The length is under 5,000 characters and it reads like a shareholder update or business progress letter rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a proxy, voting result, or management change announcement. The content is consistent with a shareholder letter or business update, which is often classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-05-30 English
Results of Annual General Meeting 3 pages 159.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement dated 31 May 2021 reporting the results of the Annual General Meeting (AGM) of HeraMED Limited. It includes detailed proxy voting results for resolutions passed at the AGM. The text explicitly states it is the "Results of Annual General Meeting" and provides voting outcomes for various resolutions. The document length is 3695 characters, which is relatively short and focused solely on voting results rather than the full AGM materials or presentations. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting. It is not the AGM presentation itself (AGM-R), nor an announcement of a report publication (RPA), nor a full annual report or other financial report. Therefore, the correct classification is DVA with high confidence.
2021-05-30 English
Updated Investor Presentation and Webinar 16 pages 3.2MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 17 May 2021, titled 'Updated Investor Presentation and Webinar'. It announces the release of an updated investor presentation and a webinar event hosted by the CEO to discuss the company's commercialisation strategy progress. The text includes detailed slides and information about the company's products, clinical trials, partnerships, corporate strategy, and management team. However, the document is primarily a presentation material and an announcement of a webinar rather than a formal financial report or regulatory filing. It does not contain financial statements, audit information, voting results, or legal proceedings. The presence of an investor presentation and webinar announcement aligns with the category 'Investor Presentation (IP)'. The document length is substantial (15,000 characters), indicating it is the presentation itself, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA). Therefore, the most appropriate classification is Investor Presentation (IP).
2021-05-16 English
Pilot agreement signed with US leader Obstetrix Medical 3 pages 198.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 May 2021 about a pilot agreement signed between HeraMED Limited and Obstetrix Medical Group. It details the terms of a commercial pilot agreement for a healthcare technology platform, including licensing and deployment plans. There are no financial statements, regulatory certifications, voting results, or management changes discussed. The content is a business update on a commercial agreement and partnership, typical of a Capital/Financing Update or general corporate announcement. Given the focus on a commercial agreement and pilot project rather than financial results or regulatory filings, the most appropriate classification is Capital/Financing Update (CAP). The document length (8564 characters) and content confirm it is a substantive announcement rather than a brief notice or report publication announcement.
2021-05-12 English
Trading Halt 2 pages 370.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from HeraMED Limited regarding a trading halt requested pending an announcement about a commercial partnership agreement. It is a short notice informing the market about the halt in trading of the company's securities and does not contain any financial data, report, or detailed information about the partnership itself. It is not a financial report, earnings release, or any detailed filing but rather a regulatory announcement related to trading status. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-10 English
Appendix 2A 15 pages 294.9KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue. This form is a regulatory announcement related to capital markets activity, specifically the listing or quotation of new securities following options exercised or convertible securities converted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) because it provides an update on the issuance and quotation of securities, which is a capital market activity.
2021-05-02 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.